Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia

Inclusion Criteria: 1. Meets the 2012 ACR revised standards and meets four or more diagnostic criteria for systemic lupus erythematosus; 2. Refractory thrombocytopenia (defined as receiving at least one course of methylprednisolone pulse therapy or intravenous injection of high-dose immunoglobulin or high-dose glucocorticoid combined with two or more Immunosuppressive drug failed and did not respond to any single drug); 3. SLEENA-SLEDAI score is greater than or equal to 8 points. If anti ds-DNA antibody is positive and/or low complement, SLEENA-SLEDAI score is greater than or equal to 6 points, or PLT count is\<10 \* 10 \^ 9/L or\<30 \* 10 \^ 9/L with bleeding tendency; 4. Age greater than or equal to 18 years old and less than or equal to 65 years old; 5. Have a stable SLE treatment plan, and participants should receive standard treatment for at least 30 days before randomization; 6. Positive Antinuclear antibody or anti ds DNA antibody; 7\. Sign informed documents. Exclusion criteria: Potential subjects who meet the inclusion criteria will be excluded if they meet any of the following criteria: 1. Patients who are allergic to tamoxifen; 2. Patients with severe active infection, history of tuberculosis, malignant tumor, HIV, hepatitis B, hepatitis C, important organs or hematopoietic stem cells/cells/bone marrow transplantation or kidney transplantation; 3. Patients with severe active central nervous system lupus and severe active lupus nephritis 4. Patients with diseases of liver, kidney, heart and other important organs, blood and Endocrine system; 5. Pregnant and lactating women; 6. Have a pregnancy preparation plan in the past year; 7. Those who have merged with other autoimmune diseases; 8. Incomplete case data and missing persons.